Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02511184
Title Crizotinib Plus Pembrolizumab In Alk-positive Advanced Non Small Cell Lung Cancer Patients
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Pfizer
Indications

lung non-small cell carcinoma

Therapies

Crizotinib

Pembrolizumab

Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
University of Alabama at Birmingham Birmingham Alabama 35233 United States Details
University of Alabama at Birmingham, IDS Pharmacy Birmingham Alabama 35249 United States Details
University of Alabama at Birmingham Birmingham Alabama 35249 United States Details
City of Hope National Medical Center Duarte California 91010 United States Details
UC San Diego Moores Cancer Center - Investigational Drug Services La Jolla California 92037-0845 United States Details
UC San Diego Medical Center - La Jolla(Thornton Hospital) La Jolla California 92037 United States Details
University Of California / San Diego Moores Cancer Center La Jolla California 92093 United States Details
UC San Diego Medical Center - Hillcrest San Diego California 92103 United States Details
Emory University Hospital Midtown Atlanta Georgia 30308 United States Details
Emory University Hospital Atlanta Georgia 30322 United States Details
The Emory Clinic Atlanta Georgia 30322 United States Details
Winship Cancer Institute of Emory University Atlanta Georgia 30322 United States Details
The Cleveland Clinic Foundation Cleveland Ohio 44195 United States Details
Swedish Cancer Institute Seattle Washington 98104 United States Details
Swedish Investigational Drug Services Pharmacy Seattle Washington 98104 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field